<DOC>
	<DOCNO>NCT00143455</DOCNO>
	<brief_summary>To compare effect irinotecan hydrochloride cisplatin `` standard '' regimen etoposide plus cisplatin overall survival , chemotherapy-naive patient newly diagnose Extensive Disease-Small Cell Lung Cancer ( ED-SCLC ) .</brief_summary>
	<brief_title>Study Of Irinotecan Hydrochloride ( Campto ( R ) ) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically cytologically proven Small Cell Lung Cancer ( SCLC ) WHO performance status : 0 , 1 No previous radiotherapy allow except bone metastasis newly diagnose . Radiotherapy allow vena cava syndrome , stent recommend ; No prior surgery primary tumor except palliative purpose ( stent vena cava syndrome ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>